Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

The following two Canadian Cancer Trials Group-led trials were recently closed to further accrual:

Canadian Cancer Trials Group IND.193 - A Phase II Study of AT7519M, A CDK Inhibitor in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia

Unfortunately, accrual to this study was below the expected rate and, despite a protocol amendment and extensive discussion, a decision to close the trial was endorsed at the Canadian Cancer Trials Group's Investigational New Drug (IND) Committee Fall Meeting call held on Nov. 15, 2013.

Canadian Cancer Trials Group IND.212 - A Pilot Study of Imetelstat given Intravenously on Day 1 and 8 of a 21 Day Schedule Alone and With Standard 13-Cis-Retinoic Acid in Children with Recurrent and/or Refractory Neuroblastoma

The company has made the decision to withdraw support for the study following a re-examination of the benefit-risk assessment for the investigational use of imetelstat in patients with recurrent and/or refractory neuroblastoma.

Thanks to all centres, staff and patients for their contributions to these studies.